MENU
+Compare
ARCT
Stock ticker: NASDAQ
AS OF
Jun 13 closing price
Price
$12.38
Change
-$0.26 (-2.06%)
Capitalization
335.75M

ARCT Arcturus Therapeutics Holdings Forecast, Technical & Fundamental Analysis

Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases... Show more

ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for ARCT with price predictions
Jun 12, 2025

ARCT saw its Stochastic Oscillator leaves the overbought zone

The Stochastic Oscillator for ARCT moved out of overbought territory on June 04, 2025. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 55 similar instances where the indicator exited the overbought zone. In of the 55 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on June 12, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on ARCT as a result. In of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARCT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for ARCT just turned positive on May 19, 2025. Looking at past instances where ARCT's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .

ARCT moved above its 50-day moving average on May 19, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for ARCT crossed bullishly above the 50-day moving average on May 22, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ARCT advanced for three days, in of 287 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 160 cases where ARCT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.436) is normal, around the industry mean (16.730). P/E Ratio (0.000) is within average values for comparable stocks, (59.666). ARCT's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.336). Dividend Yield (0.000) settles around the average of (0.040) among similar stocks. P/S Ratio (2.552) is also within normal values, averaging (257.556).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. ARCT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARCT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

ARCT is expected to report earnings to fall 717.31% to $3.21 per share on August 11

Arcturus Therapeutics Holdings ARCT Stock Earnings Reports
Q2'25
Est.
$3.21
Q1'25
Missed
by $4.11
Q4'24
Missed
by $0.92
Q3'24
Beat
by $0.31
Q2'24
Beat
by $0.38
The last earnings report on May 12 showed earnings per share of -51 cents, missing the estimate of $3.59. With 433.10K shares outstanding, the current market capitalization sits at 335.75M.
A.I. Advisor
published General Information

General Information

a developer of technology and therapeutics for rare diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
10628 Science Center Drive
Phone
+1 858 900-2660
Employees
180
Web
https://www.arcturusrx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JIGZX81.100.39
+0.48%
JPMorgan U.S. GARP Equity R2
NBPIX47.120.11
+0.23%
Neuberger Berman Large Cap Value Instl
FAFDX36.57N/A
N/A
Fidelity Advisor Financials A
UMBHX27.59N/A
N/A
Carillon Chartwell Small Cap I
MSJCX17.15N/A
N/A
Morgan Stanley Global Endurance C

ARCT and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ARCT has been loosely correlated with TRDA. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if ARCT jumps, then TRDA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARCT
1D Price
Change %
ARCT100%
+1.61%
TRDA - ARCT
50%
Loosely correlated
-0.63%
BMEA - ARCT
49%
Loosely correlated
+4.40%
ABCL - ARCT
49%
Loosely correlated
-2.48%
MRNA - ARCT
47%
Loosely correlated
-1.44%
BEAM - ARCT
47%
Loosely correlated
-2.52%
More